Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 5/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2563689 | 1.00 | TDP1 (0.48) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL23100793 | 0.99 | MAPT (0.49) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2563647 | 0.95 | TDP1 (0.48) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL14764990 | 0.92 | TDP1 (0.53) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL8269374 | 0.92 | TDP1 (0.53) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL21071153 | 0.90 | MAPT (0.54) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL30274324 | 0.89 | HPGD (0.50) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL10954191 | 0.89 | HPGD (0.50) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL25042572 | 0.89 | HPGD (0.50) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL30001029 | 0.88 | HPGD (0.47) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013183-B1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2011-11-02 | — | — | EP | disclosed |
| US-20090082378-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082378-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | ADRB2, ADRA2C, ADRB1 | TDP1 3636/4885L3MBTL1 4420/4885MAPT 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.